SHIELD: Suppressing Harmful Inflammation to Enable Lymphatic Endothelial Defense
Secondary Lymphedema (caused by trauma, surgery, infection, burns) has long been treated as a plumbing problem. But secondary lymphedema is in fact an immune-mediated disease driven by antigen-specific CD4+ T cell expansion that actively destroys lymphatic vasculature.
In this Phase 2 work, SNC is advancing engineered IL-10 and IL-35 fusion proteins that localize to the lymphatics after subcutaneous injection. These biologics directly suppress pathogenic T cells and promote local regulatory T cell (Tregs) function, shifting the lymphatic environment from chronic inflammation to active repair. This project leverages the tolerogenic engineering principles validated in Phase I STTR. In Phase I, SNC successfully reprogrammed autoimmune responses in Type 1 Diabetes, outperforming preclinical analogs of current clinical therapies.